SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

Jiang, He; Yang, Li; Zhang, Hai nan; Wang, Wei; Yang, Xiao; Qi, Huan; Li, Hua; Men, Dong; Zhou, Jie; Tao, Sheng Ce

doi:10.1038/s41467-020-17488-8

Cited by 284 publications

(326 citation statements)

References 52 publications

Supporting

Mentioning

296

Contrasting

Unclassified

Order By: Relevance

“…54,77 We speculate that the reason why more antibodies are developed to the S protein is because the S protein is on the SAR-CoV-2 surface and is more easily recognized by the immune system. 80,85 2) Standardization of sample collection. The specimen and collection time from infected patient may have great influence on the detection result.…”

Section: Prospectivementioning

confidence: 99%

COVID‐19 diagnostic testing: Technology perspective

Wang

et al. 2020

Clinical & Translational Med

View full text Add to dashboard Cite

The corona virus disease 2019 (COVID‐19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). More than 18 million people were infected with a total of 0.7 million deaths in ∼188 countries. Controlling the spread of SARS‐CoV‐2 is therefore inherently dependent on identifying and isolating infected individuals, especially since COVID‐19 can result in little to no symptoms. Here, we provide a comprehensive review of the different primary technologies used to test for COVID‐19 infection, discuss the advantages and disadvantages of each technology, and highlight the studies that have employed them. We also describe technologies that have the potential to accelerate SARS‐CoV‐2 detection in the future, including digital PCR, CRISPR, and microarray. Finally, remaining challenges in COVID‐19 diagnostic testing are discussed, including (a) the lack of universal standards for diagnostic testing; (b) the identification of appropriate sample collection site(s); (c) the difficulty in performing large population screening; and (d) the limited understanding of SARS‐COV‐2 viral invasion, replication, and transmission.

show abstract

Section: Prospectivementioning

confidence: 99%

COVID‐19 diagnostic testing: Technology perspective

Wang

et al. 2020

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…A number of studies have begun to unravel the antibody response to SARS-CoV-2 beyond a simple "yes or no" answer [9][10][11][12][13][14][15][16][17][18] . Here, we hypothesized that by examining the antibody profile in patient's serum in terms of antigens, antibody isotypes (IgG, IgM, and IgA), and neutralization, we would be able to identify specific signatures associated to effective SARS-CoV-2 neutralization.…”

Section: Introductionmentioning

confidence: 99%

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization

Noval

Rodriguez-Rodriguez

Louie

et al. 2020

Preprint

View full text Add to dashboard Cite

Understanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Here, we determine the ability of sera from 101 recovered healthcare workers to neutralize both authentic SARS-CoV-2 and SARS-CoV-2 pseudotyped virus and address their antibody titers against SARS-CoV-2 nucleoprotein and spike receptor-binding domain. Interestingly, the majority of individuals have low neutralization capacity and only 6% of the healthcare workers showed high neutralizing titers against both authentic SARS-CoV-2 virus and the pseudotyped virus. We found the antibody response to SARS-CoV-2 infection generates antigen-specific isotypes as well as a diverse combination of antibody isotypes, with high titers of IgG, IgM and IgA against both antigens correlating with neutralization capacity. Importantly, we found that neutralization correlated with antibody titers as quantified by ELISA. This suggests that an ELISA assay can be used to determine seroneutralization potential. Altogether, our work provides a snapshot of the SARS-CoV-2 neutralizing antibody response in recovered healthcare workers and provides evidence that possessing multiple antibody isotypes may play an important role in SARS-CoV-2 neutralization.

show abstract

“…Other SARS-CoV-2 proteins such as ORF9b (accessory protein 9b) and NSP5 (non-structural protein 5) also demonstrate significant antibody responses. This SARS-CoV-2 proteome microarray provides antibody profiling capabilities that support new diagnostic, treatment, and vaccination research efforts; 107 however, it includes 18/28 of the proteins encoded in the genome of SARS-CoV-2, 90 none of which were prepared using mammalian cells, potentially affecting the antibody–antigen interactions. Moreover, only 29 clinical samples were tested and, as such, increasing the number of samples and diversifying the time point of specimen collection can further reveal the dynamics of antibody profiling.…”

Section: Viral Antigen and Antibody Testsmentioning

confidence: 99%

Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance

et al. 2020

View full text Add to dashboard Cite

The disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), has led to a global pandemic with tremendous mortality, morbidity, and economic loss. The current lack of effective vaccines and treatments places tremendous value on widespread screening, early detection, and contact tracing of COVID-19 for controlling its spread and minimizing the resultant health and societal impact. Bioanalytical diagnostic technologies have played a critical role in the mitigation of the COVID-19 pandemic and will continue to be foundational in the prevention of the subsequent waves of this pandemic along with future infectious disease outbreaks. In this Review, we aim at presenting a roadmap to the bioanalytical testing of COVID-19, with a focus on the performance metrics as well as the limitations of various techniques. The state-of-the-art technologies, mostly limited to centralized laboratories, set the clinical metrics against which the emerging technologies are measured. Technologies for point-of-care and do-it-yourself testing are rapidly emerging, which open the route for testing in the community, at home, and at points-of-entry to widely screen and monitor individuals for enabling normal life despite of an infectious disease pandemic. The combination of different classes of diagnostic technologies (centralized and point-of-care and relying on multiple biomarkers) are needed for effective diagnosis, treatment selection, prognosis, patient monitoring, and epidemiological surveillance in the event of major pandemics such as COVID-19.

show abstract

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

Cited by 284 publications

References 52 publications

COVID‐19 diagnostic testing: Technology perspective

COVID‐19 diagnostic testing: Technology perspective

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization

Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance

Contact Info

Product

Resources

About